U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07463651) titled 'MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib' on Feb. 26.
Brief Summary: The study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-label, randomized, controlled trial enrolled participants and randomly assigned them in a 1:1 ratio to either the experimental group or the control group. The experimental group received maintenance therapy with gilteritinib, while the control group received maintenance therapy with sorafenib, with 297 cases in each group, totaling 594 enrolled subjects.
All patients' minimal residual dise...